Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-07-23 Regulatory Filings
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter responding to comments from the SEC staff regarding amendments to the company's Form 10-Q for the quarterly period ended March 31, 2021. It discusses corrections to certifications attached to the amended Form 10-Q and mentions filing an Amendment No. 2 to the Amended Form 10-Q. The document itself is a correspondence letter addressing regulatory comments and amendments, not the actual financial report. The length is 3165 characters, which is relatively short and consistent with a regulatory correspondence or filing rather than a full interim report. The content focuses on regulatory compliance and certification corrections rather than substantive financial data or analysis. Therefore, this document should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or other financial report type.
2021-07-23 English
AMENDMENT NO. 2 TO FORM 10-Q
Interim / Quarterly Report Q1 2021
2021-07-23 English
Regulatory Filings 2021
Regulatory Filings
2021-07-22 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC responding to comments on amendments to Form 10-K and Form 10-Q filings. It discusses corrections to certifications related to internal control over financial reporting and references specific exhibits (31.1 and 31.2). The document itself is a correspondence letter responding to regulatory comments rather than the actual financial reports. It is short (3976 characters) and primarily contains explanations and responses to SEC staff comments, not substantive financial data or the full report. Therefore, it fits the category of Regulatory Filings (RNS), which includes officer certifications, comment letters, and similar correspondence with regulators.
2021-07-21 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed comment letter from a company responding to the SEC staff's comments on a Registration Statement on Form S-4. The Form S-4 is used for business combinations, mergers, or acquisitions involving securities. The letter discusses amendments to the Registration Statement, including risk factors, financial projections, valuation, ownership interests, and pro forma financial statements related to a business combination. This is not a full annual or quarterly report, nor an earnings release or proxy statement. It is a regulatory filing responding to SEC comments on a merger-related registration statement. Therefore, the document fits best under Regulatory Filings (RNS) as it is a correspondence and amendment related to a regulatory filing rather than the filing itself or a standalone report.
2021-07-17 English
REGISTRATION STATEMENT
Merger & Acquisition Classification · 100% confidence The document is an Amendment No. 1 to Form S-4 Registration Statement filed with the SEC, dated July 16, 2021. It includes a proxy statement/prospectus related to a Business Combination involving Amplitude Healthcare Acquisition Corporation and Jasper Therapeutics, Inc. The document discusses the terms of the merger, stockholder voting, and securities registration for the transaction. Form S-4 filings are typically used for merger and acquisition transactions and related securities offerings. The presence of detailed merger terms, proxy statement, and registration of shares for the business combination clearly indicates this is related to M&A activity. Therefore, the document fits the category of Merger & Acquisition filings (MA). The document length and content confirm it is the filing itself, not just an announcement or summary, so it is not RPA or RNS.
2021-07-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.